Journal of Psychopharmacology · 2020 · 58 citations · 31 references
MedicineNeurosciencePharmacologyNeuropharmacologyPharmacodynamicsPsychopharmacologyBlood-brain Barrier PenetrationBlood-brain Barrier PharmacologyReceptor PharmacologyInflammatory Cytokine ProductionMacrophage Cytokine ProductionMood EffectsNeuroinflammatory Cytokine ResponsesP2x7 Receptor SignalingPharmacokinetics At The Blood-brain BarrierPro-inflammatory Cytokine CascadesPro-inflammatory Mediator Production
BACKGROUND: This is the first report of the pharmacodynamic (PD) effects of the selective, potent and brain-penetrant P2X7 receptor (P2X7R) antagonist JNJ-54175446. Activation of the P2X7R, an adenosine triphosphate-gated ion channel, leads to the production of pro-inflammatory cytokines, which have been linked to neuroinflammation and play a role in the pathogenesis of mood disorders. Previous clinical studies with JNJ-54175446 demonstrated peripheral target engagement of JNJ-54175446 by assessing ex vivo lipopolysaccharide (LPS)-stimulated cytokine production. Blood-brain barrier penetration and a clear dose-receptor occupancy relationship was demonstrated using positron emission tomography. AIMS: The objectives of this double-blind, placebo-controlled, translational study were to assess the safety and tolerability of administering multiple doses of JNJ-54175446 and to explore its PD effects using a dexamphetamine challenge. METHODS: = 16) and underwent a baseline oral 20 mg dexamphetamine challenge followed by 11 consecutive days q.d. dosing with JNJ-54175446/placebo and a randomised crossover dexamphetamine/placebo challenge. RESULTS: At all doses tested, JNJ-54175446 was well tolerated and suppressed the ex vivo LPS-induced release of cytokines. At doses ⩾100 mg, JNJ-54175446 attenuated dexamphetamine-induced increases in locomotion and enhanced the mood-elevating effects of dexamphetamine, suggesting that a dose that is approximately twice as high is needed to obtain a central PD response compared to the dose needed for maximum peripheral occupancy. CONCLUSION: Overall, the observed pharmacological profile of JNJ-54175446 in the dexamphetamine challenge paradigm is compatible with a potential mood-modulating effect.
31
Receptors for Purines and Pyrimidines
Geoffrey Burnstock, Alexei Verkhratsky · 2012 · 4K citations
Medicine, Biochemistry, Pharmacology +10
Tissue distribution of the P2X7 receptor
Ginetta Collo, S. Neidhart, Eric Kawashima et al. · Neuropharmacology · 1997 · 498 citations
Medicine, Neuroscience, Pharmacology +13
Thomas Stock, Bradley J. Bloom, Nathan Wei et al. · The Journal of Rheumatology · 2012 · 238 citations · Full text